[{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Partner International","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Kainos Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"KM10544","moa":"IRAK4","graph1":"Oncology","graph2":"Preclinical","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Emmaus Life Sciences \/ Emmaus","highestDevelopmentStatusID":"4","companyTruncated":"Emmaus Life Sciences \/ Emmaus"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Asembia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"L-Glutamine","moa":"NAD redox potential","graph1":"Genetic Disease","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Emmaus Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"Glutathione","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Emmaus Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Endari (L-glutamine), an amino acid, is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 13, 2023

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Endari (L-glutamine), is approved in the U.S. and several Gulf Cooperation Council countries to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 19, 2022

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Endari is a prescription grade L-glutamine oral powder which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 07, 2022

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Endari® (L-glutamine), an amino acid, is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 17, 2022

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Compared to baseline, patients had significantly fewer vaso-occlusive crises at 24, 48 and 72 weeks on Endari therapy, as well as fewer hospitalizations (median change from 3.0 to 0; p<0.00001) and fewer days in hospital (median change from 15.0 to 0; p<...

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 07, 2022

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Endari is a brand-name prescription medication. It’s FDA-approved to reduce the number of sudden complications of sickle cell disease (SCD) and how severe they are. One of the main complications is pain crisis, which is severe pain across the body.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 29, 2022

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Endari®, Emmaus' prescription grade L-glutamine oral powder, was approved by the FDA in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 04, 2022

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The agreement with Asembia is an important step for Emmaus, as their team will assist in streamlining the insurance authorization process for Endari as well as deployment of various patient assistance programs.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 04, 2021

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Recipient : Asembia

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Endari®, Emmaus’ prescription grade L-glutamine oral powder, was approved by the FDA in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.

                          Brand Name : Endari

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 26, 2021

                          Lead Product(s) : L-Glutamine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Emmaus intends to advance the licensed technology to complete in-vivo studies to determine disease selection for KM10544 which, if successful, would be followed by Investigational New Drug enabling studies.

                          Brand Name : KM10544

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 12, 2021

                          Lead Product(s) : KM10544

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Kainos Medicine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank